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Abstract
Aim: The adiponutrin gene family consists of five genes (PNPLA1-5) coding for proteins with both lipolytic and lipogenic
properties. PNPLA3 has previously been associated with adult obesity. Here we investigated the possible association
between genetic variants in these genes and childhood and adolescent obesity.
Methods/Results: Polymorphisms in the five genes of the adiponutrin gene family were selected and genotyped using the
Sequenom platform in a childhood and adolescent obesity case-control study. Six variants in PNPLA1 showed association
with obesity (rs9380559, rs12212459, rs1467912, rs4713951, rs10947600, and rs12199580, p,0.05 after adjustment for age
and gender). Three variants in PNPLA3 showed association with obesity before, but not after, adjustment for age and gender
(rs139051, rs12483959, and rs2072907, p.0.05). When analyzing these SNPs in relation to phenotypes, two SNPs in the
PNPLA3 gene showed association with insulin sensitivity (rs12483959: b=20.053, p=0.016, and rs2072907: b=20.049,
p=0.024). No associations were seen for PNPLA2, PNPLA4, and PNPLA5.
Conclusions: Genetic variation in the adiponutrin gene family does not seem to contribute strongly to obesity in children
and adolescents. PNPLA1 exhibited a modest effect on obesity and PNPLA3 on insulin sensitivity. These data, however,
require confirmation in other cohorts and ethnic groups.
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Introduction
A new family of genes with conserved patatin and lipase
domains has recently been identified and given the name patatin-
like phospholipase family [1–3]. The family consists of nine genes,
and of these, five genes form a subgroup called the adiponutrin
family [3]. This subfamily include patatin-like phospholipase 1
(PNPLA1), adipose triglyceride lipase (ATGL/PNPLA2), adiponu-
trin (ADPN/PNPLA3), gene sequence 2 (PNPLA4) and GS2-like
(PNPLA5). It is believed that members of the adiponutrin family
complement the hormone sensitive lipase (HSL) as responsible for
adipocyte triacylglycerol lipase activity. Mice lacking HSL display
a lean phenotype and accumulate diglycerides suggesting that
HSL is the main enzyme for the second step of lipolysis and that
other enzymes are responsible for the first step [4–6]. Several
studies indicate that the protein encoded by PNPLA2 is one of the
enzymes responsible for this first step in lipolysis [3,7]. Less is
known about the function of the other members but data indicates
that they retain both lipolytic and lipogenic properties [1–3].
All members of the adiponutrin gene family are highly
expressed in the adipose tissue. Expression increases during
adipocyte differentiation and is regulated in by nutritional
challenges [1–3]. For example, PNPLA3 is downregulated in the
adipose tissue of insulin resistant subjects and upregulated in a
glucose dependent fashion in response to insulin stimulation [8].
Two studies have demonstrated genetic association between
PNPLA2 and PNPLA3 with type 2 diabetes and obesity,
respectively [8–10]. Far less is known about the other three
members of the family, PNPLA1, PNPLA4 and PNPLA5. The aim
of this study was to investigate the genetic relevance of all five
genes in the adiponutrin family in the pathogenesis of childhood
obesity and insulin resistance.
Results
In total, 61 out of 85 selected SNPs were successfully genotyped
using the Sequenom platform in a childhood and adolescent obesity
case-control material (Table S1 and Figures S1, S2, S3, S4, S5).
Clinical characteristics for this cohort have been presented
previously and are summarized in Table 1 [11]. Gender distribution
was similar between the obese and non-obesechildren. By definition,
the obese group was younger than the normal weight controls
(Table 1). The obese subjects all showed a significant degree of
insulin resistance (HOMA-IR: 3.04 [2.11–4.49], n=297).
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association with obesity when adjusting for age and gender
(rs9380559, rs12212459, rs1467912, rs4713951, rs10947600 and
the coding rs12199580, Table 2 and Table S2). Three variants in
PNPLA3 showed association with obesity (rs139051, rs12483959
and rs2072907, Table 2 and Table S2). This association was
unaffected by adjustment for gender but attenuated when
adjusting for age (data not shown). No variants in the PNPLA2,
PNPLA4 and PNPLA5 were associated with obesity in this cohort
(Table S2).
The associated SNPs were further analyzed for association with
phenotypes related to obesity in the group of obese children and
adolescents (Table 3). Similar data for the control group was not
available. PNPLA1 variants rs12212459 and rs1467912 showed
association with BMI-standard deviation score (SDS) after
adjusting for age and gender (Table 3). Adjusting for insulin
resistance defined by HOMA-IR did affect this observation
(b=0.30, p=0.025 and b=0.40, p=0.0029, respectively).
PNPLA1 SNP rs10947600 was associated with both body weight
(n=330, GG: 104.3[85.1–124.8] kg, GA: 94.1[78.3–111.9] kg,
AA: 94.4[79.3–109.0] kg, b=23.38, p=0.018) and glucose levels
(n=292, GG: 4.9[4.7–5.3] mmol/L, GA: 4.9[4.6–5.2] mmol/L,
AA: 4.7[4.5–5.1] mmol/L, b=20.0077, p=0.032) and PNPLA1
SNP rs12199580 with glucose levels (n=289, CC: 4.9[4.7–5.3]
mmol/L, CA: 5.0[4.6–5.2] mmol/L, AA: 4.7[4.5–5.1] mmol/L,
b=20.0085, p=0.016).
The obesity associated PNPLA3 variants rs12483959 and
rs2072907 showed association with insulin sensitivity (Table 3)
and disposition index (rs12483959: n=264, GG: 122[66–208],
GA: 109[61–214], AA: 74[52–197], b=20.14, p=0.017 and
rs2072907: n=265, GG: 121[66–209], GC: 109[58–215], CC:
83[56–192], b=20.12, p=0.043). Adjusting for BMI-SDS did
not affect the association with insulin sensitivity (b=20.053,
p=0.015 and b=20.049, p=0.022, respectively) or disposition
index (b=20.15, p=0.012 and b=20.12, p=0.031, respective-
ly).
Discussion
The genetic analysis using TagSNPs in the five genes included
in the adiponutrin gene family revealed that some variants within
these genes exert a weak but significant effect on obesity in
children and adolescents. In this study the association was limited
to the two genes PNPLA1 and PNPLA3. Findings concerning
PNPLA3 variants were attenuated when adjusting for age and
gender but further analysis indicated that they might influence
insulin sensitivity.
Childhood obesity is associated with increased risk of cardio-
vascular disease [12] and reduced life expectancy [13,14]. It is
therefore of great importance to study this group in order to
identify markers that could recognize individuals predisposed to
obesity at an early stage. However, the polygenic nature of obesity
makes the search for risk altering genes difficult. Recent studies
have identified two strong obesity candidate genes, the fat mass
and obesity associated (FTO) and melanocortin 4 receptor (MC4R)
[15–18]. Genes involved in lipid metabolism such as lipases would
be relevant to investigate in relation with obesity since it is a state
of excessive storage of lipids. In the obese state, the adipose tissue is
less efficient in buffering lipids resulting in increased levels in the
circulation. These lipids will then be stored in other tissues thereby
promoting development of insulin resistance and possibly type 2
diabetes [19]. Genetic studies of for example the important lipase
hormone sensitive lipase (HSL) show significant associations with
measures of obesity suggesting that genes coding for proteins with
lipase activity are of importance [20–25]. The five adiponutrin
gene family members encode proteins that are able to both
catalyze the build-up and breakdown of fat thus identifying them
as possible candidate genes [1–3]. Data presented here, for the
most part, failed to clearly confirm this candidacy. We found
borderline association with obesity for PNPLA1 and PNPLA3, but
these data would not hold for multiple corrections. Given the
Table 1. Clinical characteristics of the child obesity case-
control study.
Non-obese Obese p-value
Gender (m/f) 234/257 226/240 0.79
Age (years) 17 (16–18) 13 (10–15) ,0.001
Weight (kg) 61 (55–69) 91 (73–109) ,0.001
Length (m) 1.72 (1.66–1.79) 1.61 (1.51–1.70) ,0.001
BMI (kg/m
2) 20.7 (19.5–22.3) 34.3 (30.9–38.3) ,0.001
BMI-SDS 0.36 (20.16–1.03) 5.98 (5.14–7.04)
A ,0.001
p-values are calculated using Wilcoxon Rank Sum test or chi
2 test for distributions.
APatients with data available were 463. BMI-SDS – Body Mass Index - Standard
Deviation Score.
doi:10.1371/journal.pone.0005327.t001
Table 2. Genetic variants in PNPLA1 and PNPLA3 showing significant association with obesity using logistic regression.
Gene SNP N (case/control) MAF (cases) OR 95% CI P PAdjusted
PNPLA1 rs9380559 451/484 0.43 1.42 (1.02–1.98) 0.63 0.038
rs12212459 440/464 0.41 0.70 (0.50–0.99) 0.94 0.043
rs1467912 455/482 0.37 0.71 (0.51–1.00) 0.61 0.049
rs4713951 451/479 0.46 0.71 (0.51–0.98) 0.67 0.037
rs10947600 456/482 0.41 0.72 (0.52–0.99) 0.87 0.042
rs12199580 451/485 0.41 0.70 (0.51–0.96) 0.64 0.028
PNPLA3 rs139051 453/469 0.35 0.99 (0.71–1.38) 0.014 0.97
rs12483959 450/484 0.16 0.79 (0.52–1.20) 0.023 0.27
rs2072907 455/477 0.17 0.82 (0.55–1.24) 0.041 0.35
p-values are calculated using Logistic regression including gender and age as covariates, additive model. The presented Odds ratios (OR) are adjusted for age and
gender. SNP – Single nucleotide polymorphism, MAF – Minor Allele Frequency, OR – Odds ratio, 95% CI – 95% confidence interval.
doi:10.1371/journal.pone.0005327.t002
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SNP BMI-SDS Insulin sensitivity (Si*10
25/pM/min) HOMA-IR
rs9380559 n 323 271 224
b 20.058 0.0062 20.15
p 0.60 0.73 0.47
AA 6.07 (5.19–7.20) 0.29 (0.18–0.46) 3.40 (1.99–4.91)
AG 5.61 (4.97–5.68) 0.33 (0.19–0.48) 3.38 (2.46–4.52)
GG 6.03 (5.29–6.71) 0.37 (0.25–0.49) 3.22 (2.35–4.40)
rs12212459 n 316 268 220
b 0.24 0.0098 0.012
p 0.036 0.58 0.96
AA 5.76 (4.86–6.67) 0.32 (0.19–0.43) 3.44 (2.48–4.61)
AC 5.76 (5.15–6.85) 0.33 (0.19–0.49) 3.38 (2.24–4.90)
CC 6.07 (5.30–7.56) 0.33 (0.21–0.52) 3.30 (1.80–4.48)
rs1467912 n 329 276 229
b 0.26 0.0048 20.068
p 0.022 0.80 0.76
CC 5.82 (4.95–6.68) 0.32 (0.19–0.45) 3.36 (2.45–4.61)
CT 5.66 (5.08–6.69) 0.34 (0.20–0.51) 3.35 (2.10–4.74)
TT 6.22 (5.53–7.61) 0.32 (0.21–0.46) 3.43 (2.27–4.63)
rs4713951 n 326 275 228
b 0.22 20.014 20.080
p 0.052 0.45 0.72
CC 5.66 (4.98–6.68) 0.33 (0.20–0.47) 3.30 (2.45–4.19)
CT 5.81 (5.02–6.90) 0.31 (0.18–0.49) 3.64 (2.34–4.83)
TT 6.11 (5.37–7.37) 0.33 (0.22–0.42) 3.19 (1.92–4.53)
rs10947600 n 327 275 228
b 0.024 0.015 20.28
p 0.83 0.41 0.20
GG 5.89 (4.97–6.88) 0.33 (0.18–0.48) 3.56 (2.49–5.03)
GA 5.83 (5.12–6.93) 0.33 (0.21–0.48) 3.25 (2.31–4.55)
AA 5.83 (5.02–7.01) 0.28 (0.19–0.45) 3.24 (1.89–4.78)
rs12199580 n 323 271 224
b 0.078 0.0067 20.38
p 0.48 0.72 0.088
CC 5.82 (4.92–6.68) 0.34 (0.19–0.49) 3.54 (2.46–5.21)
CA 5.87 (5.14–6.97) 0.33 (0.21–0.47) 3.33 (2.45–4.54)
AA 5.83 (5.14–7.05) 0.28 (0.19–0.45) 3.07 (1.83–4.61)
rs139051 n 326 274 227
b 20.060 20.0223 0.14
p 0.59 0.23 0.46
GG 5.90 (4.98–7.15) 0.33 (0.22–0.50) 3.43 (2.37–4.58)
GA 5.75 (5.00–6.57) 0.33 (0.18–0.47) 3.35 (2.30–4.80)
AA 5.95 (5.14–6.89) 0.30 (0.21–0.42) 3.61 (2.34–4.75)
rs12483959 n 324 274 228
b 0.029 20.053 20.30
p 0.83 0.016 0.25
GG 5.83 (5.00–7.09) 0.33 (0.21–0.49) 3.32 (2.36–4.63)
GA 5.81 (5.05–6.54) 0.33 (0.16–0.42) 3.56 (2.39–5.03)
AA 6.14 (5.28–7.32) 0.34 (0.28–0.65) 2.50 (2.14–4.00)
rs2072907 n 327 275 229
b 0.034 20.049 20.21
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underline that the results should be interpreted with caution and
need confirmation elsewhere.
So far little is known concerning genetic variation in the
adiponutrin gene family and its possible influence on metabolic
disease. Only the PNPLA2 and PNPLA3 have been studied in this
context before. For PNPLA2, common variants has been associated
with free fatty acid levels, triglyceride levels and type 2 diabetes
suggesting that the gene may play an important role for the risk
factors associated with obesity rather than obesity per se [9]. Rare
mutations in the PNPLA2 gene, resulting in a truncated protein
with no capacity to bind to lipid droplets but with an intact patatin
domain, has been identified in a subgroup of patients with neutral
lipid storage disorder (NLSD) with mild myopathy [26]. NLSD is a
disorder characterized by storage of triglyceride-containing
cytoplasmic droplets in for example leukocytes, bone marrow,
skin and muscle (OMIM #610717). In our study we did not find
any association between PNPLA2 and obesity and therefore no
further analysis was conducted. As stated in both previous studies
regarding PNPLA2, no association was found with obesity and the
NLSD patients carrying PNPLA2 mutations were not obese [9,26].
Genetic variants in PNPLA3 have previously been associated
with obesity [8]. In this study we confirm these data but also
demonstrate an association with insulin sensitivity. The association
with obesity disappears when adjusting for age while that with
insulin sensitivity association remains. Data may suggest that
variants in PNPLA3 rather affect insulin sensitivity. Although obese
adolescents in general are insulin resistant, the degree of obesity is
not a major determining factor [27] and together with age,
cardiorespiratory fitness, and truncal fat, only 25% of individual
variation can be explained [28]. Thus, it is likely that genetic
vulnerability is of importance and it is possible that PNPLA3
variation may play a role It has been shown that both genetic
variants and insulin resistance regulate adipose PNPLA3 gene
expression [8,29].
Genetic variants in the PNPLA1, PNPLA4 and PNPLA5 genes
have not been studied before. We found an association between
PNPLA1 and juvenile obesity but no associations were found for
PNPLA4 or PNPLA5. These data need to be replicated due to the
relatively small study material used in this study.
In conclusion, although members of the adiponutrin gene family
are clear candidate genes for obesity we were unable to clearly
confirm this candidacy for obesity in children and adolescents. We
did find a modest effect of PNPLA1 on obesity and PNPLA3 on
insulin sensitivity although these data need confirmatory studies.
Furthermore, although PNPLA2, PNPLA4 and PNPLA5 did not
show any significant association with obesity and insulin sensitivity,
we cannot rule out a possible implication in the pathogenesis due
to the low power of this study.
Materials and Methods
Study subjects
We studied 466 obese children and adolescents referred to the
National Childhood Obesity Centre at Karolinska University
Hospital and Karolinska Institute and 491 non-obese adolescents
recruited from 17 upper secondary schools around Stockholm
(Table 1) [11]. For the obese children we had available blood
samples, growth charts, clinical journal notes, medical examina-
tion and laboratory reports as well as questionnaires completed by
the parents of the children at enrolment. The lean adolescents
were asked through the school nurse if they wanted to participate
in the study. Blood was collected and every adolescent completed a
questionnaire concerning ethnicity, health and the use of medical
drugs. Subjects with overweight/obesity or chronic diseases were
excluded from the control group.
Height (Ulmer Stadiometer, Ulm, Germany), and weight (Vetek
TI-1200, Va ¨ddo ¨, Sweden) were measured with subjects in light
clothing and body mass index (BMI; kg/m
2) calculated. Body
weight and height was measured at the first visit to the nearest
0.1 kg and 1 cm, respectively. All subjects in the obese group were
obese according to international age and sex adjusted standards
[30]. Values of a BMI standard deviation score (BMI-SDS) was
calculated from weight, height, age and gender based on a French
material from 1982 [31]. All subjects gave their written informed
consent and the Regional Committee of Ethics, Stockholm,
approved the study. The study was conducted according to the
principles of the Helsinki Declaration.
Laboratory analysis
Blood samples from the obese children for measurement of
glucose, (glucose-6-phosphate dehydrogenase method, Kebo Lab,
Stockholm, Sweden), insulin (Pharmacia Diagnostics AB, Uppsala,
Sweden), HDL-cholesterol and triglycerides (Boehringer, Man-
nheim, Germany) were obtained after an over-night fast. Analyses
were performed at a certified laboratory (Department of Clinical
Chemistry, Karolinska University Hospital). The control subjects
were not fasting when the blood samples were obtained. Therefore
insulin and glucose were measured only in the obese cohort.
Insulin resistance was estimated by homeostasis model of
assessment (HOMA-IR) [32]. Insulin sensitivity index representing
the effect of insulin to catalyze the clearance of glucose from
plasma after an intravenous glucose load were calculated using the
Bergman minimal model approach [11,33]. Acute insulin response
reflects the first phase of endogenous secretion in response to
glucose infusion and was calculated as area under the curve during
the first 10 minutes [11,34]. Genomic DNA was prepared by
standard methods. DNA was extracted from whole blood by using
QiaGen MaxiPrep (QiaGen, Germany) at the DNA/RNA
SNP BMI-SDS Insulin sensitivity (Si*10
25/pM/min) HOMA-IR
p 0.79 0.024 0.40
GG 5.81 (4.99–7.04) 0.33 (0.22–0.49) 3.29 (2.35–4.63)
GC 5.88 (5.02–6.65) 0.27 (0.16–0.42) 3.56 (2.39–4.72)
CC 6.24 (5.47–7.16) 0.33 (0.25–0.64) 2.67 (2.28–4.48)
p-values are calculated using multiple regression including gender and age as covariates. SNP – Single nucleotide polymorphism. n – number of observations, b–
Regression coefficient, p - p-value for t-statistic. f – fasting samples, BMI-SDS – Body Mass Index - Standard Deviation Score, HOMA-IR – homeostasis model of
assessment - Insulin Resistance.
doi:10.1371/journal.pone.0005327.t003
Table 3. Cont.
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Polygenic Disease, Lund University, Malmo ¨ University Hospital,
Malmo ¨, Sweden.
Genotyping
SNPs were selected by using data from the HapMap consortium
for each of the sequences coding for the selected five genes
including an extra 5000 bases upstream and downstream [35].
TagSNPs were then selected using Tagger in the Haploview
program for all five genes [36]. Additional coding SNPs were
selected from the National Center for Biotechnology Information
(NCBI) SNP database (http://www.ncbi.nlm.nih.gov/SNP/). In
total, 85 SNPs passed the assay design and were genotyped using
the Sequenom platform (MALDI-TOF) at the DNA/RNA
Genotyping Lab, SWEGENE Resource Center for Profiling
Polygenic Disease, Lund University, Malmo ¨ University Hospital,
Malmo ¨, Sweden. 24 SNPs failed genotyping and Hardy Weinberg
equilibrium. These SNPs were removed from further analysis
leaving a total of 61 SNPs for analysis (Table S1 and Figures S1,
S2, S3, S4, S5). A selection of SNPs were re-analyzed in a subset of
283 patients using the TaqMan allelic discrimination method on
the ABI 7900HT according to manufacturers’ recommendations
(Applied Biosystems). Success rate was 98.6%.
Statistical analysis
Logistic regression with age and gender as covariates were used
for estimating the genotype association. Linear multiple regres-
sions were performed in order to test for SNP effects on obesity
and insulin resistance (HOMA-IR) as quantitative traits. All traits
were log transformed for normal distribution. These analyses were
adjusted for age and gender. Also, the obesity analysis was
adjusted for insulin resistance and vice versa insulin resistance
analysis for obesity. All p-values are based on additive models for
the genetic variants. Data are presented as median with
interquartile range within brackets [25
th–75
th] or odds ratio
(OR) with 95% confidence interval (CI). All statistical calculations
were performed using PLINK (http://pngu.mgh.harvard.edu/
˜purcell/plink/index.shtml) [37]. Furthermore, the power to detect
an additive OR of 1.2 in this material when the minor allele
frequency (MAF) is 0.05 is 17% and 53% for a MAF of 0.5 when a
is set at 0.05.
Supporting Information
Table S1 Hardy Weinberg equilibrium (HWE) for genetic
variants analyzed in the Adiponutrin gene family.
Found at: doi:10.1371/journal.pone.0005327.s001 (0.12 MB
DOC)
Table S2 Variants in the five genes in the Adiponutrin gene
family and the association with obesity using logistic regression
analyses.
Found at: doi:10.1371/journal.pone.0005327.s002 (0.12 MB
DOC)
Figure S1 Graphical overview of the patatin-like phospholipase
1( PNPLA1) gene and linkage disequilibrium obtained from
HapMap (http://www.hapmap.org/). SNPs successfully geno-
typed by MALDI-TOF MS are marked with a black square.
Found at: doi:10.1371/journal.pone.0005327.s003 (0.62 MB
PNG)
Figure S2 Graphical overview of the patatin-like phospholipase
2( PNPLA2) gene and linkage disequilibrium obtained from
HapMap (http://www.hapmap.org/). SNPs successfully geno-
typed by MALDI-TOF MS are marked with a black square. One
SNP, the rs1138693, is not included since it was not present in the
HapMap database at the time of data extraction. It was included
in the study because it is a coding SNP.
Found at: doi:10.1371/journal.pone.0005327.s004 (0.01 MB
PNG)
Figure S3 Graphical overview of the patatin-like phospholipase
3( PNPLA3) gene and linkage disequilibrium obtained from
HapMap (http://www.hapmap.org/). SNPs successfully geno-
typed by MALDI-TOF MS are marked with a black square.
Found at: doi:10.1371/journal.pone.0005327.s005 (0.26 MB
PNG)
Figure S4 Graphical overview of the patatin-like phospholipase
4( PNPLA4) gene and linkage disequilibrium obtained from
HapMap (http://www.hapmap.org/). SNPs successfully geno-
typed by MALDI-TOF MS are marked with a black square.
Found at: doi:10.1371/journal.pone.0005327.s006 (0.06 MB
PNG)
Figure S5 Graphical overview of the patatin-like phospholipase
5( PNPLA5) gene and linkage disequilibrium obtained from
HapMap (http://www.hapmap.org/). SNPs successfully geno-
typed by MALDI-TOF MS are marked with a black square.
Found at: doi:10.1371/journal.pone.0005327.s007 (0.17 MB
PNG)
Author Contributions
Conceived and designed the experiments: LEJ CM MR. Performed the
experiments: LEJ LMJ. Analyzed the data: LEJ. Contributed reagents/
materials/analysis tools: PD SN SJ CM MR. Wrote the paper: LEJ CM
MR.
References
1. Jenkins CM, Mancuso DJ, Yan W, Sims HF, Gibson B, et al. (2004)
Identification, cloning, expression, and purification of three novel human
calcium-independent phospholipase A2 family members possessing triacylgly-
cerol lipase and acylglycerol transacylase activities. J Biol Chem 279:
48968–48975.
2. Lake AC, Sun Y, Li JL, Kim JE, Johnson JW, et al. (2005) Expression,
regulation, and triglyceride hydrolase activity of Adiponutrin family members.
J Lipid Res 46: 2477–2487.
3. Wilson PA, Gardner SD, Lambie NM, Commans SA, Crowther DJ (2006)
Characterization of the human patatin-like phospholipase family. J Lipid Res 47:
1940–1949.
4. Osuga J, Ishibashi S, Oka T, Yagyu H, Tozawa R, et al. (2000) Targeted
disruption of hormone-sensitive lipase results in male sterility and adipocyte
hypertrophy, but not in obesity. Proc Natl Acad Sci U S A 97: 787–
792.
5. Mulder H, Sorhede-Winzell M, Contreras JA, Fex M, Strom K, et al. (2003)
Hormone-sensitive lipase null mice exhibit signs of impaired insulin sensitivity
whereas insulin secretion is intact. J Biol Chem 278: 36380–36388.
6. Wang SP, Laurin N, Himms-Hagen J, Rudnicki MA, Levy E, et al. (2001) The
adipose tissue phenotype of hormone-sensitive lipase deficiency in mice. Obes
Res 9: 119–128.
7. Wolf G (2005) The mechanism and regulation of fat mobilization from adipose
tissue: desnutrin, a newly discovered lipolytic enzyme. Nutr Rev 63: 166–170.
8. Johansson LE, Hoffstedt J, Parikh H, Carlsson E, Wabitsch M, et al. (2006)
Variation in the adiponutrin gene influences its expression and associates with
obesity. Diabetes 55: 826–833.
9. Schoenborn V, Heid IM, Vollmert C, Lingenhel A, Adams TD, et al. (2006)
The ATGL gene is associated with free fatty acids, triglycerides, and type 2
diabetes. Diabetes 55: 1270–1275.
10. Johansson LE, Lindblad U, Larsson CA, Rastam L, Ridderstrale M (2008)
Polymorphisms in the adiponutrin gene are associated with increased insulin
secretion and obesity. Eur J Endocrinol 159: 577–583.
11. Jacobsson JA, Danielsson P, Svensson V, Klovins J, Gyllensten U, et al. (2008)
Major gender difference in association of FTO gene variant among severely
obese children with obesity and obesity related phenotypes. Biochem Biophys
Res Commun 368: 476–482.
PNPLA Gene Family and Obesity
PLoS ONE | www.plosone.org 5 April 2009 | Volume 4 | Issue 4 | e532712. Baker JL, Olsen LW, Sorensen TI (2007) Childhood body-mass index and the
risk of coronary heart disease in adulthood. N Engl J Med 357: 2329–2337.
13. Fontaine KR, Redden DT, Wang C, Westfall AO, Allison DB (2003) Years of
life lost due to obesity. JAMA 289: 187–193.
14. Mossberg HO (1989) 40-year follow-up of overweight children. Lancet 2:
491–493.
15. Loos RJ, Lindgren CM, Li S, Wheeler E, Zhao JH, et al. (2008) Common
variants near MC4R are associated with fat mass, weight and risk of obesity. Nat
Genet 40: 768–775.
16. Chambers JC, Elliott P, Zabaneh D, Zhang W, Li Y, et al. (2008) Common
genetic variation near MC4R is associated with waist circumference and insulin
resistance. Nat Genet 40: 716–718.
17. Frayling TM, Timpson NJ, Weedon MN, Zeggini E, Freathy RM, et al. (2007)
A common variant in the FTO gene is associated with body mass index and
predisposes to childhood and adult obesity. Science 316: 889–894.
18. Dina C, Meyre D, Gallina S, Durand E, Korner A, et al. (2007) Variation in
FTO contributes to childhood obesity and severe adult obesity. Nat Genet 39:
724–726.
19. Frayn KN (2002) Adipose tissue as a buffer for daily lipid flux. Diabetologia 45:
1201–1210.
20. Klannemark M, Orho M, Langin D, Laurell H, Holm C, et al. (1998) The
putative role of the hormone-sensitive lipase gene in the pathogenesis of Type II
diabetes mellitus and abdominal obesity. Diabetologia 41: 1516–1522.
21. Magre J, Laurell H, Fizames C, Antoine PJ, Dib C, et al. (1998) Human
hormone-sensitive lipase: genetic mapping, identification of a new dinucleotide
repeat, and association with obesity and NIDDM. Diabetes 47: 284–286.
22. Qi L, Shen H, Larson I, Barnard JR, Schaefer EJ, et al. (2004) Genetic variation
at the hormone sensitive lipase: gender-specific association with plasma lipid and
glucose concentrations. Clin Genet 65: 93–100.
23. Lavebratt C, Ryden M, Schalling M, Sengul S, Ahlberg S, et al. (2002) The
hormone-sensitive lipase i6 gene polymorphism and body fat accumulation.
Eur J Clin Invest 32: 938–942.
24. Hoffstedt J, Arner P, Schalling M, Pedersen NL, Sengul S, et al. (2001) A
common hormone-sensitive lipase i6 gene polymorphism is associated with
decreased human adipocyte lipolytic function. Diabetes 50: 2410–2413.
25. Garenc C, Perusse L, Chagnon YC, Rankinen T, Gagnon J, et al. (2002) The
hormone-sensitive lipase gene and body composition: the HERITAGE Family
Study. Int J Obes Relat Metab Disord 26: 220–227.
26. Fischer J, Lefevre C, Morava E, Mussini JM, Laforet P, et al. (2007) The gene
encoding adipose triglyceride lipase (PNPLA2) is mutated in neutral lipid storage
disease with myopathy. Nat Genet 39: 28–30.
27. Ro ¨ssner SM, Neovius M, Montgomery SM, Marcus C, Norgren S (2008)
Alternative Methods of Insulin Sensitivity Assessment in Obese Children and
Adolescents Diabetes Care. 2008 31: 802–804.
28. Morinder G, Larsson UE, Norgren S, Marcus C (2009) Insulin sensitivity,
VO2max and body composition in severely obese Swedish children and
adolescents. Acta Paediatr 98: 132–138.
29. Baulande S, Lasnier F, Lucas M, Pairault J (2001) Adiponutrin, a transmem-
brane protein corresponding to a novel dietary- and obesity-linked mRNA
specifically expressed in the adipose lineage. J Biol Chem 276: 33336–33344.
30. Cole TJ, Bellizzi MC, Flegal KM, Dietz WH (2000) Establishing a standard
definition for child overweight and obesity worldwide: international survey. BMJ
320: 1240–1243.
31. Rolland-Cachera MF, Sempe M, Guilloud-Bataille M, Patois E, Pequignot-
Guggenbuhl F, et al. (1982) Adiposity indices in children. Am J Clin Nutr 36:
178–184.
32. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al. (1985)
Homeostasis model assessment: insulin resistance and beta-cell function from
fasting plasma glucose and insulin concentrations in man. Diabetologia 28:
412–419.
33. Bergman RN (2005) Minimal model: perspective from 2005. Horm Res 64
(Suppl 3): 8–15.
34. Bergman RN (1989) Lilly lecture 1989. Toward physiological understanding of
glucose tolerance. Minimal-model approach. Diabetes 38: 1512–1527.
35. The International HapMap Project. Nature 426: 789–796.
36. Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and
visualization of LD and haplotype maps. Bioinformatics 21: 263–265.
37. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007)
PLINK: a tool set for whole-genome association and population-based linkage
analyses. Am J Hum Genet 81: 559–575.
PNPLA Gene Family and Obesity
PLoS ONE | www.plosone.org 6 April 2009 | Volume 4 | Issue 4 | e5327